332348-12-6
中文名稱
Unii-7D0yb67S97
英文名稱
Unii-7D0yb67S97
CAS
332348-12-6
基本信息
中文別名
化合物 T10218 英文別名
CTLA4lgOrencia
Ctla4-ig
Abatacept
Bms-188667
Bms 188667
Unii-7D0yb67S97
1-25-Oncostatin m (human precursor) fusion protein with ctla-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimol (146-146')-disulfide
Unii-7D0yb67S97價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-108829A | Unii-7D0yb67S97 Abatacept (powder) | 332348-12-6 | 1 mg | 4800元 |
| 2026/06/05 | HY-108829 | Unii-7D0yb67S97 Abatacept | 332348-12-6 | 1mg | 4000元 |
| 2025/05/22 | HY-108829 | Unii-7D0yb67S97 Abatacept | 332348-12-6 | 5mg | 8200元 |
常見(jiàn)問(wèn)題列表
生物活性
Abatacept (CTLA4lg) 是一種可溶性融合蛋白，由人 CTLA4 的胞外結(jié)構(gòu)域和人 IgG1 Fc 部分的片段 (鉸鏈，CH2 和 3 結(jié)構(gòu)域) 組成。Abatacept 是選擇性 T 細(xì)胞共刺激調(diào)節(jié)劑，也是一種用于自身免疫性疾病的蛋白藥物。體內(nèi)研究
Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t
obs
= 2.50) paw edema reduction compared with the IV dose group.
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V
ss
) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2
–/–
BALB/c (H-2d/d) mice.
| Animal Model: | Male Lewis rats (6-9 weeks old) with weights of 150-175 g |
| Dosage: | 10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 |
| Administration: | IV or SC |
| Result: | Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t obs = 2.50) paw edema reduction compared with the IV dose group. |
| Animal Model: | Male Lewis rats (6-9 weeks old) with weights of 150-175 g |
| Dosage: | 10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study) |
| Administration: | IV or SC |
| Result: | The NCA clearance (CL) is 20.8 mL/day/kg, volume (V ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%. |